SCHEMBL2876196

SCHEMBL2876196

O=[N+]([O-])c1ccc(OCc2ccccc2)c(C(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
MAPT P10636 1/20 0.61
CYP19A1 P11511 9/20 0.54
CYP11B1 P15538 2/20 0.54
CYP11B2 P19099 2/20 0.54
MRGPRX4 Q96LA9 3/20 0.48
RXRA P19793 2/20 0.48
RXRB P28702 2/20 0.48
RXRG P48443 2/20 0.48
PPIA P62937 1/20 0.46
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
PTGES O14684 1/20 0.46
CNR1 P21554 1/20 0.46
ACHE P22303 1/20 0.46
CNR2 P34972 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30354835 1.00 MEN1 (0.61) MEN1KMT2AMAPTCYP19A1CYP11B1
Acetonitrile SCHEMBL27483725 0.93 MEN1 (0.57) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL544327 0.90 MEN1 (0.59) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL16048718 0.89 MAPT (0.49) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL29151250 0.88 RXRA (0.56) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL11012747 0.87 CYP19A1 (0.56) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL29151267 0.87 CYP19A1 (0.56) MEN1KMT2AMAPTCYP19A1RXRA
SCHEMBL30354937 0.87 CYP19A1 (0.56) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL6680617 0.84 MEN1 (0.62) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL371728 0.83 MEN1 (0.70) MEN1KMT2AMAPTCYP19A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101503359-B Preparation of 2,5-bis(2-trifluoromethyl-4-nitrophenoxy) toluol UNIV DONGHUA 2013-10-09 CN claimed
CN-101560164-B Preparation method of 2,5-bi(2-trifluoromethyl-4-aminophenoxyl)toluene UNIV DONGHUA 2013-06-26 CN claimed
CN-101560164-A Preparation method of 2,5-bi(2-trifluoromethyl-4-aminophenoxyl)toluene UNIV DONGHUA (CN) 2009-10-21 CN claimed
CN-101503359-A Preparation of 2,5-bis(2-trifluoromethyl-4-nitrophenoxy) toluol UNIV DONGHUA (CN) 2009-08-12 CN claimed
US-20260078092-A1 SULFONYL CARBOXAMIDE COMPOUND, THEIR DERIVATIVES, AND USES THEREOF SHAH SALIM (US) 2026-03-19 US disclosed
US-20230278965-A1 NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-09-07 US disclosed
EP-4169916-A1 CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF Korea Institute of Science and Technology (KR) 2023-04-26 EP disclosed
CN-115955968-A Carbohydrazone acyldinitrile compounds comprising at least two aryl or heteroaryl groups connected by a novel linker and uses thereof 韩国科学技术研究院 2023-04-11 CN disclosed
US-20160339027-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2016-11-24 US disclosed
US-20160051551-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-25 US disclosed
US-9199973-B2 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors NOVARTIS AG (CH) 2015-12-01 US disclosed
US-20150065527-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2015-03-05 US disclosed
CN-1346271-A Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA UK LTD (SE) 2002-04-24 CN disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
EP-1047694-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-11-02 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed
WO-1999035146-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-07-15 WO disclosed
EP-0782570-A1 SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE THE WELLCOME FOUNDATION LIMITED (GB) 1997-07-09 EP disclosed
WO-1996009294-A1 SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE THE WELLCOME FOUNDATION LIMITED (GB) 1996-03-28 WO disclosed
US-4166735-A Cycloalkanecarboxanilide derivative herbicides SHELL OIL COMPANY (US) 1979-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078092-A1 SULFONYL CARBOXAMIDE COMPOUND, THEIR DERIVATIVES, AND USES THEREOF ATP2A1, ATP2A2, ATP2A3 MEN1 3024/4885KMT2A 2940/4885MAPT 4615/4885
US-20230278965-A1 NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF AADAC, CBR3, MTCL3 MEN1 1484/4885KMT2A 929/4885MAPT 2830/4885
US-20160339027-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ABL1, ERBB2, SRC MEN1 2579/4885KMT2A 1174/4885MAPT 1036/4885
US-20160051551-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ABL1, ERBB2, SRC MEN1 2579/4885KMT2A 1174/4885MAPT 1036/4885
US-20150065527-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ABL1, ERBB2, SRC MEN1 2579/4885KMT2A 1174/4885MAPT 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.